Group items tagged

Tomorrow is the big day! We finally see how Human Genome Sciences Blockbuster Hopes on Lupus Drug Benlysta Pans Out based on Human Genome Sciences Benlysta® Drug Approval for Lupus Patients (HGSI) by the FDA Panel Notes. At our Trading School, we've been covering this stock for some times and we're very pleased with the drug benefits that Benlysta® brings to patients worldwide. We've seen positive results in near-term and long-term periods and we expect the FDA to clear Benlysta on December 9, 2010 and we expect positive FDA Panel notes tomorrow November 12, 2010.

Human Genome Sciences Benlysta FDA Drug Approval for Lupus Patients. Human Genome Sciences HGSI Special Biotech Future Video. SMF Reiterates Strong Buy Rating on Human Genome

StockMarketFunding.com reports that Human Genome Sciences FDA Panel Recommendation for Benlysta may cause many large biotechnology players to look at HGSI as a takeover target.

Dendreon Provenge Approval Call Summary (45.50 +5.88) -Update : During the call, the co said that it will provide Provenge to 2000 patients in next 12 months. Co said that demand for Provenge will exceed co's ability to provide it in the first 12 months; will continue build out of manufacturing capabilities. Mgmt said that 1 infusion will cost $31k; complete course will cost $93k. and EPS of $1.65.